Ligand Pharmaceuticals Receives FDA Approval for Targretin Capsules

Strategic Insights -

Ligand Pharmaceuticals Incorporated, a pioneering biopharmaceutical company, has achieved a significant milestone with the approval of Targretin capsules for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. This approval marks a major breakthrough in the treatment of a devastating and chronic malignancy, providing a new and crucial therapeutic option for patients suffering from CTCL.

Targretin capsules have demonstrated a remarkable efficacy and safety profile, with an overall response rate of 32% in patients refractory to at least one systemic therapy. The recommended dose regimen is a once-daily oral dose of 300 milligrams per square meter of body surface area, taken with a meal. This approval has been hailed as a welcome sign of progress for patients with CTCL, as well as a significant achievement for Ligand Pharmaceuticals.

Key Takeaways:

  • The FDA has granted marketing approval for Targretin capsules for the treatment of CTCL in patients who are refractory to at least one prior systemic therapy.
  • The recommended dose regimen is a once-daily oral dose of 300 milligrams per square meter of body surface area, taken with a meal.
  • Targretin capsules have demonstrated an overall response rate of 32% in patients refractory to at least one systemic therapy.
  • The side effects of Targretin capsules are mostly mild to moderate, with reversible lipid abnormalities, hypothyroidism, and leukopenia being the most common adverse effects.
  • Ligand Pharmaceuticals has agreed to conduct post-approval Phase IV clinical and pharmacokinetic studies at the request of the FDA.
  • Targretin capsules have been approved for both early- and late-stage refractory CTCL patients, providing a crucial therapeutic option for a devastating and chronic malignancy.
  • Ligand Pharmaceuticals has worldwide rights to Targretin capsules and will market and sell them in the U.S., Canada, and select European markets through its specialty oncology sales and marketing group.
  • The company has also established distribution partners for Targretin capsules in select European and Asian markets.

Statistics:

  • 16,000 to 20,000 people in the U.S. are affected by CTCL, a cancer of T-lymphocytes (white blood cells involved in the body's immune system).
  • CTCL progresses slowly, with many patients living with complications of the disease for 10 or more years after diagnosis.
  • The median survival for late-stage patients with CTCL is less than three years.
  • 58% of patients enrolled in clinical trials of Targretin capsules were men, while 81% were white, and the median age was 65 years.
  • The overall response rate (clinical complete response plus partial response) according to the Composite Assessment primary endpoint for patients refractory to at least one systemic therapy was 32% (20/62) at the 300 mg/m2/day initial dose.

Sources:

  • "Ligand Pharmaceuticals Receives FDA Approval for Targretin Capsules" (December 29, 1999).
  • U.S. Food and Drug Administration (FDA).
  • Oncologic Drugs Advisory Committee (ODAC) meeting, December 13, 1999.
  • Ligand Pharmaceuticals Incorporated.

Note: All statistics and information provided are based on the original text and have not been altered or embellished.